Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Chong Kun Dang Pharmaceutical: Clinical Trials & FDA Approval Profile

Chong Kun Dang Pharmaceutical (Global / Institutional) sponsors 27 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 3 active protocols (3 recruiting now), 15 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)0.0%
Median Closed Enrollment vs National (145 pts)172 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Chong Kun Dang Pharmaceutical
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)27
Active Pipeline (Recruiting Now)3 (3)
Completed vs Stopped Early15 / 0 (0.0%)
Median Closed Actual Enrollment172 participants
Physical Hospital Site Disclosure91.8% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Chong Kun Dang Pharmaceutical
Hospital Research SiteLocationShared Protocols
Seoul National University HospitalSeoul6
Korea University Guro HospitalSeoul5
The Catholic University of Korea, Seoul St. Mary's HospitalSeoul3

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Chong Kun Dang Pharmaceutical
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT03726853The Clinical Trial to Evaluate the Efficacy and Safety of CKD-497Phase IICOMPLETED
NCT03437785Clinical Trial to Evaluate the Efficacy and Safety of CKD-495 TabletPhase IICOMPLETED
NCT04255589A Clinical Trial to Evaluate the Efficacy and Safety of CKD-495Phase IIICOMPLETED

Explore interactive annual charts and M&A subsidiary rollups in the Chong Kun Dang Pharmaceutical Interactive Dossier, benchmark peers in Cardiovascular and Thrombosis, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI